Company intelligence / Profile preview

SPRIM Global Investments

Singapore, Singaporesprim.net ↗

Ownership: Private
Development stage: Other

Overview

SPRIM Global Investments (SGI) specializes in providing equity investment, debt financing (including venture debt), and royalty financing to high-potential biotech and medtech companies globally. Its focus is on supporting the advancement of clinical trials from preclinical through late-stage development by leveraging its network of R&D services/CROs and digital health technology partners. In March 2025 it announced a $300 million joint venture with One Investment Management to expand its specialized trial financing platform TrialCap.

Modalities: Small moleculeBiologicDigital health solutionsMedical devices
Industry: Investors

Partnerships

One Investment Management (clinical trial financing via TrialCap)

Beyond the preview

Go deeper on SPRIM Global Investments.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPRIM Global Investments.

Explore the full profile